WOOJUNG BIO, Inc. (KOSDAQ:215380)
South Korea · Delayed Price · Currency is KRW 1,770.00
0.00 (0.00%)
At close: Sep 19, 2025
WOOJUNG BIO Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 36,596 | 43,200 | 38,616 | 46,918 | 31,238 | 37,344 | Upgrade |
Other Revenue | 0 | - | -0 | - | - | - | Upgrade |
| 36,596 | 43,200 | 38,616 | 46,918 | 31,238 | 37,344 | Upgrade | |
Revenue Growth (YoY) | -18.23% | 11.87% | -17.70% | 50.20% | -16.35% | 15.65% | Upgrade |
Cost of Revenue | 25,783 | 30,613 | 32,427 | 40,291 | 25,490 | 32,107 | Upgrade |
Gross Profit | 10,812 | 12,586 | 6,189 | 6,626 | 5,748 | 5,237 | Upgrade |
Selling, General & Admin | 9,098 | 8,522 | 8,287 | 6,881 | 7,686 | 6,817 | Upgrade |
Research & Development | 622.27 | 505.84 | 294.44 | 614.06 | 538.26 | 620.94 | Upgrade |
Other Operating Expenses | 248.46 | 232.96 | 218.17 | 202.1 | 196.91 | 38.55 | Upgrade |
Operating Expenses | 12,193 | 10,802 | 10,213 | 9,148 | 9,609 | 10,642 | Upgrade |
Operating Income | -1,381 | 1,785 | -4,025 | -2,521 | -3,861 | -5,404 | Upgrade |
Interest Expense | -3,019 | -3,228 | -3,225 | -2,797 | -648.62 | -54.02 | Upgrade |
Interest & Investment Income | 59.06 | 31.72 | 55.26 | 78 | 51.23 | 103.55 | Upgrade |
Earnings From Equity Investments | -3.11 | -3 | - | - | - | - | Upgrade |
Currency Exchange Gain (Loss) | -27.4 | -50.28 | -37.65 | -45.53 | 68.61 | -27.7 | Upgrade |
Other Non Operating Income (Expenses) | -326.01 | 1,248 | 3,953 | 4,358 | 1,336 | -3,452 | Upgrade |
EBT Excluding Unusual Items | -4,697 | -217.38 | -3,280 | -927.89 | -3,054 | -8,835 | Upgrade |
Gain (Loss) on Sale of Investments | -20.63 | -44.33 | 5.51 | -28.94 | 1,182 | -1,714 | Upgrade |
Gain (Loss) on Sale of Assets | 17.22 | -48.6 | 27.2 | -61.77 | -53.59 | -16.01 | Upgrade |
Asset Writedown | 560.38 | 560.38 | - | -846.94 | - | -3.06 | Upgrade |
Other Unusual Items | - | -24.77 | -1,807 | - | - | - | Upgrade |
Pretax Income | -4,140 | 225.3 | -5,054 | -1,866 | -1,926 | -10,568 | Upgrade |
Income Tax Expense | - | - | - | 14.66 | - | 310.22 | Upgrade |
Net Income | -4,140 | 225.3 | -5,054 | -1,880 | -1,926 | -10,879 | Upgrade |
Net Income to Common | -4,140 | 225.3 | -5,054 | -1,880 | -1,926 | -10,879 | Upgrade |
Shares Outstanding (Basic) | 16 | 15 | 13 | 13 | 12 | 12 | Upgrade |
Shares Outstanding (Diluted) | 16 | 16 | 13 | 13 | 12 | 12 | Upgrade |
Shares Change (YoY) | 22.66% | 23.46% | -0.65% | 7.66% | 3.36% | 15.90% | Upgrade |
EPS (Basic) | -256.25 | 15.43 | -395.00 | -146.00 | -161.00 | -940.00 | Upgrade |
EPS (Diluted) | -308.29 | -26.00 | -395.00 | -146.00 | -161.00 | -940.00 | Upgrade |
Free Cash Flow | -3,425 | -1,419 | -4,065 | -8,919 | -34,956 | -24,340 | Upgrade |
Free Cash Flow Per Share | -211.96 | -89.83 | -317.71 | -692.61 | -2922.44 | -2103.16 | Upgrade |
Gross Margin | 29.54% | 29.13% | 16.03% | 14.12% | 18.40% | 14.03% | Upgrade |
Operating Margin | -3.77% | 4.13% | -10.42% | -5.37% | -12.36% | -14.47% | Upgrade |
Profit Margin | -11.31% | 0.52% | -13.09% | -4.01% | -6.17% | -29.13% | Upgrade |
Free Cash Flow Margin | -9.36% | -3.28% | -10.53% | -19.01% | -111.90% | -65.18% | Upgrade |
EBITDA | 2,591 | 5,986 | 298.17 | 1,726 | -1,160 | -3,819 | Upgrade |
EBITDA Margin | 7.08% | 13.86% | 0.77% | 3.68% | -3.71% | -10.22% | Upgrade |
D&A For EBITDA | 3,971 | 4,202 | 4,323 | 4,247 | 2,701 | 1,586 | Upgrade |
EBIT | -1,381 | 1,785 | -4,025 | -2,521 | -3,861 | -5,404 | Upgrade |
EBIT Margin | -3.77% | 4.13% | -10.42% | -5.37% | -12.36% | -14.47% | Upgrade |
Advertising Expenses | - | 104.22 | 50.59 | 95.36 | 48.75 | 112.24 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.